Abiopharma

🔍 Hartree Partners, LP (Executive)

Company: HUDSON TECHNOLOGIES INC /NY (HDSN)

Report Date: 2026-08-24

Detailed Transactions and Holdings:

• Acquired 9,446 shares of Common Stock, par value $0.01 at $5.5 per share (Direct)
  Date: 2026-08-24 | Code: P | equity_swap_involved: 0 | shares_owned_after: 5,108,834.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 91,166 shares of Common Stock, par value $0.01 at $5.4965 per share (Direct)
  Date: 2026-08-25 | Code: P | equity_swap_involved: 0 | shares_owned_after: 5,200,000.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
• F2: Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.4800 to $5.5000, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.